A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

Ki vehet részt

• Patients aged 12 years or older at the time of informed consent/assent
• Physician decision to treat the patient with dupilumab for chronic spontaneous urticaria (CSU) made prior to and independently of the patient's participation in the study
• Patient is able to understand and complete study-related questionnaires
• Patients and/or parent/legally authorized representative provide voluntary informed consent and/or assent to participate in the study before inclusion in the study

Ki nem vehet részt

• Prior use of dupilumab within 6 months of the baseline assessment; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
• Any condition that the treating physician or virtual Investigator believes may interfere with the patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments
• Patients who have a contraindication to dupilumab according to the approved prescribing information label
• Patients currently participating in any interventional clinical trial